Imigran FDT

Imigran FDT

sumatriptan

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Sumatriptan succinate
Indications/Uses
Acute relief of migraine w/ or w/o aura, including migraine attacks associated w/ menstrual period.
Dosage/Direction for Use
Adult Single 50 or 100 mg dose. If no response to 1st dose, a 2nd dose should not be taken for the same attack. If patient responded to the 1st dose, but symptoms recur, a 2nd dose may be given in the next 24 hr provided not >300 mg is taken in any 24-hr period.
Administration
May be taken with or without food: Swallow whole. For patients w/ swallowing difficulties, disperse tab in a small amount of water.
Contraindications
Hypersensitivity. Previous MI, ischaemic heart disease (IHD), Prinzmetal's angina/coronary vasospasm, peripheral vascular disease or patients who have symptoms or signs consistent w/ IHD. History of CVA or transient ischaemic attack. Uncontrolled HTN, severe hepatic impairment. Concomitant therapy w/ MAOIs, ergotamine or its derivatives.
Special Precautions
Potentially serious neurological conditions underlying CV disease. Hypersensitivity to sulphonamides. Controlled HTN. Hepatic or renal impairment. History of seizures, lowered seizure threshold. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn. Elderly >65 yr.
Adverse Reactions
Dizziness, drowsiness, paraesthesia, hypoaesthesia; transient increase in BP, flushing; dyspnoea; nausea & vomiting; sensations of heaviness; pain, sensations of heat or cold, pressure or tightness; weakness, fatigue.
Drug Interactions
Not to be given w/ ergotamine, MAOIs. Serotonin syndrome w/ SSRI/selective nonadrenaline reuptake inhibitors. Not recommended w/ 5HT1 agonist.
ATC Classification
N02CC01 - sumatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Presentation/Packing
Form
Imigran FDT tab 50 mg
Packing/Price
2's
Form
Imigran FDT tab 100 mg
Packing/Price
2's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in